Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pelvic Pain
Conditions
Pelvic Pain
Trial Timeline
Jun 1, 2024 → Nov 2, 2025
NCT ID
NCT06279195About Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet
Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet is a phase 2 stage product being developed by Pfizer for Pelvic Pain. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT06279195. Target conditions include Pelvic Pain.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06279195 | Phase 2 | Withdrawn |
Competing Products
11 competing products in Pelvic Pain
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Solifenacin + Placebo | Astellas Pharma | Approved | 85 |
| BGS649 + Placebo | Novartis | Phase 2 | 52 |
| Tanezumab + Placebo | Pfizer | Phase 2 | 51 |
| Azithromycin | Pfizer | Phase 3 | 76 |
| Vaginal estrogen + Placebo | Pfizer | Pre-clinical | 22 |
| Conjugated Estrogens Cream + Placebo Cream | Pfizer | Approved | 84 |
| BAY1834845 + Placebo | Bayer | Phase 1 | 30 |
| Ofloxacin + Avelox (Moxifloxacin, BAY12-8039) | Bayer | Phase 3 | 74 |
| Moxifloxacin (Avelox, BAY12-8039) + Levofloxacin & Metronidazole | Bayer | Phase 3 | 74 |
| Dienogest (BAY86-5258, Visanne) | Bayer | Pre-clinical | 20 |
| Sevoflurane + propofol + remifentanil | Baxter | Approved | 82 |